Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, including evolving cellular therapies, and their availability on site. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes [1-3]. Since the last edition, innovative cellular and gene therapies have entered in activity across indications affecting clinical decision making. As the number and type of regulatory authority-approved cellular therapies grow, recommendations for best practice and quality of patient care were developed to support clinicians and will be regularly updated.

Authors

Institutions

Publication Details

Journal
Bone Marrow Transplantation
Published
2025-09-09
DOI
https://doi.org/10.1038/s41409-025-02701-3
Citations
3
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Krzysztof Kałwak, Bénédicte Neven, Donal P. McLornan, Raffaella Greco et al.
3 citations
Bone Marrow Transplantation
CAR-T cell therapy research
3.14
article

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Krzysztof Kałwak, Bénédicte Neven, Donal P. McLornan, Raffaella Greco, John A. Snowden, Fabio Ciceri, Isabel Sánchez‐Ortega, Ali Bazarbachi, Tobias Alexander, Antonio M. Risitano, Michelle Kenyon, Hilda Mekelenkamp, Zinaida Perić, Mette D. Hazenberg, Paolo Pedrazzoli, Diana Averbuch, Emanuele Angelucci, Anna Sureda, Annalisa Ruggeri
article en
3 citations

Abstract

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, including evolving cellular therapies, and their availability on site. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes [1-3]. Since the last edition, innovative cellular and gene therapies have entered in activity across indications affecting clinical decision making. As the number and type of regulatory authority-approved cellular therapies grow, recommendations for best practice and quality of patient care were developed to support clinicians and will be regularly updated.

Bone Marrow TransplantationVol. 60(11)
University College London Hospitals NHS Foundation Trust (GB), University of Rijeka (HR), Vita-Salute San Raffaele University (IT), Hebrew University of Jerusalem (IL), University of Pavia (IT), Hadassah Medical Center (IL), Leiden University Medical Center (NL), Intensive Care Foundation (AU), Foundation Center (US), Sanquin (NL), Wroclaw Medical University (PL), Humboldt-Universität zu Berlin (DE), Institut d'Investigació Biomédica de Bellvitge (ES), German Rheumatism Research Centre (DE), Assistance Publique – Hôpitaux de Paris (FR), Sheffield Teaching Hospitals NHS Foundation Trust (GB), Institut Català d'Oncologia (ES), King's College Hospital NHS Foundation Trust (GB), Azienda Ospedaliera S.Giuseppe Moscati (IT), IRCCS Ospedale San Raffaele (IT), Ospedale Policlinico San Martino (IT), Policlinico San Matteo Fondazione (IT), Amsterdam University Medical Centers (NL), University College London (GB), Universitat de Barcelona (ES), University of Amsterdam (NL), University of Sheffield (GB), American University of Beirut (LB)
Openalex Percentile: Top 7%
CAR-T cell therapy research
3.14
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.